[Detection of hyperplasia and cancer of the endometrium].
The authors propose a test consisting of the administration of a progestogen for 7 days in women menopausal for more than two years, with the aim of detecting occult endometrial hyperplasia. Given the frequent association between hyperplasia and cancer, further investigations are carried out in every case in which bleeding occurs. The value of this trial is discussed and compared with other methods put forward for endometrial cancer screening.
D000367:Age Factors; D001706:Biopsy; D003536:Cystadenocarcinoma / Q000175:diagnosis* / Q000473:pathology; D003537:Cystadenoma / Q000175:diagnosis* / Q000473:pathology; D003581:Cytodiagnosis; D004714:Endometrial Hyperplasia / Q000175:diagnosis* / Q000473:pathology; D004717:Endometrium / Q000473:pathology; D005188:False Negative Reactions; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D045167:Progesterone Congeners; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000473:pathology; D014626:Vaginal Smears
D045167:Progesterone Congeners
Dépistage des hyperplasies et des cancers de l'endomètre.